Pharmacology of Betamethasone

Introduction/Overview

Betamethasone, a potent synthetic glucocorticoid, represents a cornerstone agent within the corticosteroid class of medications. Its development marked a significant advancement in therapeutic options for managing inflammatory, allergic, and autoimmune conditions. As a fluorinated derivative of prednisolone, betamethasone exhibits enhanced glucocorticoid receptor affinity and reduced mineralocorticoid activity, which underpins its clinical utility and distinct adverse effect profile. The drug’s pharmacology is characterized by profound anti-inflammatory and immunosuppressive actions, mediated through complex genomic and non-genomic pathways. Mastery of betamethasone’s pharmacological principles is essential for clinicians to harness its therapeutic benefits while mitigating the risks associated with systemic corticosteroid administration.

The clinical relevance of betamethasone extends across numerous medical specialties, including dermatology, rheumatology, pulmonology, obstetrics, and hematology. Its formulations, ranging from oral tablets and injectable solutions to topical creams and lotions, allow for tailored therapeutic approaches based on disease severity and target tissue. A thorough understanding of its pharmacokinetic behavior, particularly its long duration of action, is critical for appropriate dosing and scheduling to minimize hypothalamic-pituitary-adrenal (HPA) axis suppression. The importance of this agent is further underscored by its role in accelerating fetal lung maturation when administered prenatally, a standard intervention in threatened preterm delivery that has significantly improved neonatal outcomes.

Learning Objectives

• Describe the chemical classification of betamethasone and its relationship to glucocorticoid and mineralocorticoid receptor activity.
• Explain the genomic and non-genomic mechanisms of action through which betamethasone exerts its anti-inflammatory and immunosuppressive effects.
• Analyze the pharmacokinetic profile of betamethasone, including absorption, distribution, metabolism, and excretion, and relate these properties to dosing regimens.
• Identify the approved therapeutic indications for betamethasone, common off-label uses, and the rationale for its selection in specific clinical scenarios.
• Evaluate the spectrum of adverse effects associated with betamethasone therapy, strategies for monitoring, and management of corticosteroid-related toxicity.

Classification

Betamethasone is classified primarily within the broader therapeutic category of corticosteroids. Its classification can be delineated across chemical, pharmacological, and therapeutic dimensions, which collectively inform its clinical application.

Therapeutic and Pharmacological Classification

Therapeutically, betamethasone is a glucocorticoid. Pharmacologically, it is categorized as a high-potency, long-acting synthetic corticosteroid. Unlike endogenous cortisol, betamethasone is engineered to maximize glucocorticoid effects while minimizing mineralocorticoid activity. This selective profile distinguishes it from other corticosteroids like hydrocortisone, which possesses significant mineralocorticoid activity, or fludrocortisone, which is primarily a mineralocorticoid. Within the hierarchy of glucocorticoid potency, betamethasone is considered one of the most potent agents, with an anti-inflammatory potency approximately 25-30 times that of hydrocortisone. Its duration of action is classified as long, with a biological half-life exceeding 36 hours, which dictates once-daily or alternate-day dosing schedules to reduce HPA axis suppression.

Chemical Classification

Chemically, betamethasone is a halogenated steroid. It is a 9-alpha-fluoro, 16-beta-methyl derivative of prednisolone. The systematic name is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione. The introduction of the fluorine atom at the 9-alpha position significantly enhances glucocorticoid receptor binding affinity and anti-inflammatory potency. The addition of a methyl group at the 16-beta position is a critical structural modification that virtually abolishes mineralocorticoid activity. This modification prevents the molecule from inducing sodium retention and potassium excretion, a common dose-limiting side effect of earlier corticosteroids. Betamethasone exists as a mixture of epimers, primarily betamethasone dipropionate and betamethasone valerate in topical formulations, and as betamethasone sodium phosphate or acetate in injectable forms, each with differing solubility and release profiles.

Mechanism of Action

The pharmacological effects of betamethasone are mediated predominantly through its action as an agonist at the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. The resulting effects are a combination of genomic (transcriptional) and non-genomic (rapid) pathways, with the genomic mechanisms accounting for the majority of its therapeutic and adverse effects.

Genomic Mechanisms: Transcriptional Regulation

Following passive diffusion across the cell membrane, betamethasone binds to the cytosolic glucocorticoid receptor. In its inactive state, the GR is complexed with heat shock proteins (HSPs) 90 and 70, and immunophilin FKBP52. Ligand binding induces a conformational change, causing dissociation of the chaperone proteins, dimerization of the receptor-ligand complex, and rapid translocation into the nucleus. Within the nucleus, the betamethasone-GR complex exerts its effects via two primary genomic mechanisms:

1. Transactivation: The dimer binds to specific DNA sequences known as glucocorticoid response elements (GREs) located in the promoter regions of target genes. This binding recruits coactivator complexes, leading to increased transcription of anti-inflammatory proteins. Key proteins induced include:
   • Annexin-1 (lipocortin-1): Inhibits phospholipase A2, reducing the release of arachidonic acid and subsequent synthesis of pro-inflammatory prostaglandins and leukotrienes.
   • IκBα: The inhibitor of nuclear factor kappa B (NF-κB). Increased IκBα sequesters NF-κB in the cytoplasm, preventing its nuclear translocation and the transcription of numerous cytokines (e.g., IL-1, IL-2, IL-6, TNF-α).
   • Glucocorticoid-induced leucine zipper (GILZ): Suppresses AP-1 and NF-κB activity and inhibits T-cell activation.
2. Transrepression: This is considered the primary mechanism for the anti-inflammatory effects. The betamethasone-GR monomer interacts with and inhibits the activity of key pro-inflammatory transcription factors, such as NF-κB and activator protein-1 (AP-1), without direct DNA binding. This interaction prevents these factors from activating the transcription of genes encoding cytokines, chemokines, adhesion molecules, and inflammatory enzymes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

Non-Genomic Mechanisms

Rapid effects, occurring within minutes of administration, are mediated through non-genomic pathways. These may involve:

• Interaction with membrane-bound GRs or other membrane receptors.
• Modulation of secondary messenger systems (e.g., reducing intracellular calcium influx).
• Inhibition of the release of pre-formed inflammatory mediators from mast cells and basophils.

These mechanisms may contribute to the rapid symptomatic relief observed in conditions like acute asthma exacerbations or severe allergic reactions.

Cellular and Systemic Effects

The molecular actions translate into broad cellular and systemic effects:

• Immunosuppression: Redistribution of lymphocytes (lymphopenia), inhibition of T-cell proliferation and function, reduced antigen presentation by dendritic cells and macrophages, and decreased immunoglobulin production.
• Anti-inflammatory: Decreased capillary permeability, inhibition of leukocyte migration and phagocytosis, and stabilization of lysosomal membranes.
• Metabolic Effects: Stimulation of gluconeogenesis, promotion of protein catabolism and lipolysis, and induction of peripheral insulin resistance.
• Other Effects: Inhibition of bone formation, suppression of fibroblast activity, and potentiation of vascular responsiveness to catecholamines.

Pharmacokinetics

The pharmacokinetic profile of betamethasone is characterized by high bioavailability, extensive distribution, hepatic metabolism, and renal excretion. Its long half-life is a defining feature with significant clinical implications for dosing frequency and HPA axis suppression.

Absorption

Betamethasone is well absorbed from the gastrointestinal tract, with oral bioavailability estimated to be over 70%. Absorption is rapid, with peak plasma concentrations (C_max) typically achieved within 1 to 2 hours post-administration. The presence of food does not appear to significantly alter the extent of absorption, though it may delay the time to reach C_max. For parenteral administration, the absorption rate depends on the ester formulation. Betamethasone sodium phosphate is highly water-soluble, providing rapid onset of action following intramuscular or intravenous injection. In contrast, betamethasone acetate is a poorly soluble depot formulation, resulting in a slow, sustained release from the injection site over several weeks. Topical absorption is variable and depends on factors such as the vehicle, skin integrity, occlusion, and the surface area treated; significant systemic absorption can occur if applied over large areas, on thin skin, or under occlusion.

Distribution

Following absorption, betamethasone is widely distributed throughout body tissues. Its volume of distribution is approximately 1.4 L/kg. The drug crosses the blood-brain barrier and the placenta. In the plasma, approximately 60-70% of betamethasone is bound to proteins, primarily transcortin (corticosteroid-binding globulin, CBG) with lower affinity for albumin. The binding is saturable at higher doses, leading to an increased fraction of unbound, pharmacologically active drug. The concentration in synovial fluid and other inflammatory sites is generally proportional to plasma concentrations.

Metabolism

Betamethasone undergoes extensive hepatic metabolism, primarily via the cytochrome P450 (CYP) 3A4 isoenzyme. The major metabolic pathways involve reduction of the 4,5 double bond and the 3-keto group, followed by conjugation with sulfate or glucuronic acid. The 9-alpha-fluoro group is not removed metabolically, which contributes to the drug’s metabolic stability and prolonged half-life. The metabolites are predominantly pharmacologically inactive. Hepatic disease may impair the metabolism of betamethasone, potentially necessitating dose adjustment in patients with severe liver impairment, although the enzyme-inducing effects of betamethasone itself can complicate this relationship.

Excretion

The elimination of betamethasone is primarily renal. The conjugated metabolites are excreted in the urine, with a small fraction eliminated unchanged. Less than 5% is excreted in the bile and subsequently in the feces. The plasma elimination half-life (t_1/2) of betamethasone is long, ranging from 36 to 54 hours. This extended half-life is a function of its high receptor affinity and slow dissociation from the glucocorticoid receptor, as well as its metabolic stability. The biological half-life, reflecting the duration of physiological effect, is even longer, up to 72 hours. This prolonged action supports once-daily dosing but also increases the risk of cumulative effects and HPA axis suppression with chronic use. Total body clearance is relatively low, approximately 0.2 L/h/kg.

Therapeutic Uses/Clinical Applications

Betamethasone is employed in a wide array of clinical conditions where potent anti-inflammatory or immunosuppressive action is required. Its use is guided by the severity of the condition, the desired onset and duration of action, and the specific formulation.

Approved Indications

• Endocrine Disorders: Primary or secondary adrenal insufficiency (in combination with a mineralocorticoid), congenital adrenal hyperplasia.
• Rheumatic Disorders: Active rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, psoriatic arthritis, acute bursitis, and epicondylitis (often via intra-articular or soft tissue injection).
• Collagen Vascular Diseases: Systemic lupus erythematosus (during acute flares), acute rheumatic carditis, polymyositis, and dermatomyositis.
• Dermatological Diseases: Severe psoriasis, severe seborrheic dermatitis, severe atopic dermatitis, exfoliative dermatitis, contact dermatitis, and pemphigus (often using topical or intralesional formulations).
• Allergic States: Control of severe or incapacitating allergic conditions refractory to conventional treatment, such as seasonal or perennial allergic rhinitis, bronchial asthma, serum sickness, and drug hypersensitivity reactions.
• Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes affecting the eye (e.g., allergic conjunctivitis, keratitis, optic neuritis, sympathetic ophthalmia) using ophthalmic formulations.
• Respiratory Diseases: Symptomatic sarcoidosis, idiopathic eosinophilic pneumonias, and as part of management for Pneumocystis jirovecii pneumonia in AIDS patients.
• Hematologic Disorders: Idiopathic thrombocytopenic purpura (ITP), acquired hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia.
• Neoplastic Diseases: Palliative management of leukemias and lymphomas in adults, and acute leukemia in childhood.
• Edematous States: To induce diuresis or remission of proteinuria in nephrotic syndrome (without uremia).
• Gastrointestinal Diseases: To induce remission in ulcerative colitis and Crohn’s disease.
• Nervous System: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumors.
• Obstetric Use: Antenatal administration for fetal lung maturation in women at risk of preterm delivery between 24 and 34 weeks of gestation. A typical regimen is two 12 mg doses of betamethasone sodium phosphate intramuscularly, 24 hours apart.

Common Off-Label Uses

• Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): Often used as part of combination antiemetic regimens for highly emetogenic chemotherapy.
• COVID-19 and Severe Pneumonia: Used in hospitalized patients with severe COVID-19 requiring supplemental oxygen or mechanical ventilation, based on evidence from trials like RECOVERY, though dexamethasone is more commonly studied.
• Acute Spinal Cord Injury: High-dose methylprednisolone has been historically used, but betamethasone may be considered in some protocols, though this practice is controversial.
• Alcoholic Hepatitis: In selected patients with severe disease, corticosteroids like betamethasone may be used to reduce inflammation.
• Thyroid Eye Disease: Used to reduce inflammation and edema in active, moderate-to-severe disease.

Adverse Effects

The adverse effects of betamethasone are extensions of its physiological and pharmacological actions and are generally dose- and duration-dependent. They can be categorized by the organ systems affected.

Common Side Effects

• Endocrine: HPA axis suppression, cushingoid appearance (moon face, central obesity, buffalo hump), hyperglycemia, glucose intolerance, growth suppression in children.
• Musculoskeletal: Proximal myopathy, muscle weakness, osteoporosis, vertebral compression fractures, aseptic necrosis of the femoral and humeral heads, tendon rupture.
• Gastrointestinal: Dyspepsia, peptic ulcer disease (risk increased with concurrent NSAIDs), pancreatitis, abdominal distention.
• Dermatological: Impaired wound healing, skin atrophy, striae, ecchymoses, facial erythema, hirsutism.
• Neuropsychiatric: Insomnia, euphoria, mood swings, depression, anxiety, psychosis, cognitive dysfunction.
• Ophthalmic: Posterior subcapsular cataracts, glaucoma, increased intraocular pressure.
• Fluid and Electrolyte: Although betamethasone has minimal mineralocorticoid activity, high doses can still cause fluid retention, hypertension, hypokalemia, and metabolic alkalosis.
• Immunological: Increased susceptibility to infections, masking of signs of infection, potential reactivation of latent tuberculosis or viral infections (e.g., herpes simplex, varicella-zoster).

Serious/Rare Adverse Reactions

• Severe HPA Axis Suppression: Leading to adrenal crisis upon withdrawal, especially if therapy is stopped abruptly after prolonged use.
• Opportunistic Infections: Such as Pneumocystis jirovecii pneumonia, systemic fungal infections, disseminated strongyloidiasis.
• Severe Psychiatric Reactions: Mania, severe depression, or suicidal ideation.
• Avascular Necrosis: Particularly of weight-bearing joints.
• Anaphylactoid Reactions: Rare, but reported with intravenous administration.
• Pancreatitis.
• Pseudotumor Cerebri: Especially upon dosage reduction or withdrawal.

No specific black box warning exists for betamethasone alone that is distinct from the general class warnings for systemic corticosteroids. However, class-wide warnings include the risk of serious and fatal infections, alterations in glucose control, psychiatric effects, and adrenal insufficiency upon withdrawal.

Drug Interactions

Betamethasone participates in numerous pharmacokinetic and pharmacodynamic drug interactions, which can alter its efficacy or toxicity, or the effects of concomitant medications.

Major Pharmacokinetic Interactions

• Enzyme Inducers: Drugs such as phenytoin, phenobarbital, carbamazepine, and rifampin induce CYP3A4 activity, potentially increasing the metabolic clearance of betamethasone and reducing its therapeutic effect. Dose adjustment may be necessary.
• Enzyme Inhibitors: Potent CYP3A4 inhibitors like ketoconazole, itraconazole, clarithromycin, and ritonavir may decrease betamethasone metabolism, leading to increased plasma concentrations and an elevated risk of corticosteroid toxicity.
• Aspirin and Other Salicylates: Corticosteroids may increase the renal clearance of salicylates, lowering their serum levels. Conversely, upon corticosteroid withdrawal, salicylate levels may rise, potentially leading to toxicity. Furthermore, the combined use increases the risk of gastrointestinal ulceration.

Major Pharmacodynamic Interactions

• Diuretics (especially potassium-depleting, e.g., thiazides, loop diuretics): Concomitant use can exacerbate hypokalemia. The hyperglycemic effect of corticosteroids may also antagonize the effects of potassium-sparing diuretics like amiloride.
• Anticoagulants (Warfarin): Corticosteroids may alter the response to warfarin, either increasing or decreasing the anticoagulant effect. Close monitoring of the International Normalized Ratio (INR) is required.
• Antidiabetic Agents (Insulin, Oral Hypoglycemics): Betamethasone antagonizes the hypoglycemic effect of these agents by promoting gluconeogenesis and inducing insulin resistance, necessitating dose adjustments of antidiabetic therapy.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use significantly increases the risk of gastrointestinal ulceration and bleeding. The combination may also impair renal function, especially in volume-depleted patients.
• Live Vaccines: Administration of live or live-attenuated vaccines (e.g., MMR, varicella, yellow fever) is contraindicated in patients receiving immunosuppressive doses of betamethasone due to the risk of vaccine-induced disease. Inactivated vaccines may have a diminished immunogenic response.
• Neuromuscular Blocking Agents: Corticosteroids may potentiate or antagonize the effects of these agents, and myopathy may be exacerbated.
• Cardiac Glycosides (Digoxin): Hypokalemia induced by corticosteroids can predispose patients to digitalis toxicity.

Contraindications

Absolute contraindications to systemic betamethasone therapy include:

• Systemic fungal infections (unless used for the management of drug reactions to amphotericin B).
• Known hypersensitivity to betamethasone or any component of the formulation.
• Administration of live virus vaccines in patients receiving immunosuppressive doses.
• Intrathecal administration (due to risk of severe neurological adverse events).

Relative contraindications, requiring careful risk-benefit assessment, include active or latent tuberculosis, active peptic ulcer disease, uncontrolled hypertension, congestive heart failure, diabetes mellitus, osteoporosis, psychotic tendencies, and active infection.

Special Considerations

Use in Pregnancy and Lactation

Pregnancy: Betamethasone is classified as Pregnancy Category C (US FDA) or recommended for use in specific clinical situations by other agencies. The drug crosses the placenta. Its use for fetal lung maturation between 24-34 weeks’ gestation is well-established and considered to have a favorable risk-benefit profile, significantly reducing the incidence of neonatal respiratory distress syndrome, intraventricular hemorrhage, and neonatal mortality. However, repeated courses or use outside this indication may be associated with potential risks, including low birth weight, reduced head circumference, and possible effects on fetal brain development. Chronic maternal use throughout pregnancy can lead to fetal adrenal suppression. Use should be restricted to clear indications where the benefit to the mother outweighs the potential fetal risk.

Lactation: Betamethasone is excreted in human milk in small quantities. Systemic corticosteroid therapy is not an absolute contraindication to breastfeeding. However, because of the potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Using the lowest effective dose and monitoring the infant for signs of corticosteroid effects (e.g., poor weight gain) is prudent.

Pediatric Considerations

Corticosteroids like betamethasone can inhibit growth in children. Growth suppression is a dose-dependent effect mediated through the inhibition of collagen synthesis and somatomedin production, as well as a direct antagonism of the action of growth hormone at the epiphyseal cartilage. Long-term therapy requires careful monitoring of linear growth. The use of alternate-day dosing regimens may minimize this effect. Dosing in children is typically based on body surface area or weight (mg/kg), rather than fixed adult doses. The psychological effects of corticosteroids, including mood changes, may be more pronounced in children. Furthermore, children on immunosuppressive doses are at particular risk from varicella and measles infections; exposure may necessitate prophylactic treatment.

Geriatric Considerations

Elderly patients may be particularly susceptible to certain adverse effects of betamethasone. Age-related increases in the prevalence of hypertension, diabetes, osteoporosis, and glaucoma can be exacerbated by corticosteroid therapy. The risk of corticosteroid-induced myopathy, which can contribute to falls and functional decline, is increased. Pharmacokinetic changes in the elderly, such as reduced hepatic metabolism or renal excretion, are possible but not consistently pronounced for betamethasone. However, the presence of comorbid conditions and polypharmacy increases the likelihood of significant drug interactions. The principle of using the lowest effective dose for the shortest possible duration is especially critical in this population.

Renal and Hepatic Impairment

Renal Impairment: Dose adjustment is not typically required for renal impairment alone, as the kidney primarily excretes inactive metabolites. However, caution is warranted due to the increased risk of fluid retention, hypertension, and electrolyte disturbances (hypokalemia) in patients with compromised renal function. The drug’s effects on protein catabolism may also worsen uremic symptoms. Monitoring of blood pressure, weight, and serum electrolytes is essential.

Hepatic Impairment: Since betamethasone is extensively metabolized in the liver, significant hepatic impairment could theoretically reduce its clearance and prolong its half-life, potentially increasing the risk of toxicity. However, the clinical data are limited. In patients with cirrhosis, hypoalbuminemia may decrease protein binding, increasing the free fraction of active drug. Careful monitoring for signs of corticosteroid excess and consideration of dose reduction are advisable in patients with severe liver disease. Conversely, betamethasone can itself elevate serum transaminase levels.

Summary/Key Points

• Betamethasone is a high-potency, synthetic glucocorticoid with minimal mineralocorticoid activity, due to its 9-alpha-fluoro and 16-beta-methyl chemical structure.
• Its primary mechanism of action involves genomic effects via the cytosolic glucocorticoid receptor, leading to transactivation of anti-inflammatory genes and transrepression of pro-inflammatory transcription factors like NF-κB and AP-1.
• Pharmacokinetically, it is well-absorbed, widely distributed, metabolized hepatically by CYP3A4, and renally excreted, with a characteristically long plasma half-life of 36-54 hours.
• Key therapeutic applications span endocrine, rheumatic, dermatologic, allergic, hematologic, and neoplastic disorders, with a critical role in antenatal fetal lung maturation.
• Adverse effects are extensive, dose-related, and involve multiple organ systems; common issues include HPA axis suppression, hyperglycemia, osteoporosis, myopathy, increased infection risk, and neuropsychiatric effects.
• Significant drug interactions occur with enzyme inducers/inhibitors, anticoagulants, antidiabetics, NSAIDs, diuretics, and live vaccines.
• Special caution is required in pregnancy (benefit for lung maturation vs. potential fetal risks), pediatrics (growth suppression), geriatrics (exacerbation of comorbidities), and in patients with hepatic impairment.

Clinical Pearls

• The long biological half-life of betamethasone permits once-daily morning dosing to mimic the circadian rhythm of cortisol and reduce HPA axis suppression.
• For chronic conditions, always employ the lowest effective dose and consider alternate-day therapy to minimize adverse effects.
• Never discontinue chronic therapy abruptly; a gradual tapering schedule is mandatory to avoid adrenal insufficiency.
• Monitor for “silent” adverse effects: regular assessment of bone mineral density, blood glucose, blood pressure, ocular pressure, and growth in children is essential during prolonged treatment.
• In patients on immunosuppressive doses, have a high index of suspicion for infection, as classic signs like fever and inflammation may be masked.
• When using for fetal lung maturation, the complete course is two 12 mg IM doses 24 hours apart; single doses or incomplete courses are suboptimal.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.